Table 3. Binary and multivariate logistic regression analysis of selected factors associated with willingness to participate in HIV vaccine studies, among participants of the RV363 study, at screening visit.
| Variables | Willingness to participate | |||
|---|---|---|---|---|
| Screening visit assessment (n = 567)a) | ||||
| Bivariate Analysis | Multivariate Analysisb) | |||
| OR (CI 95%) | p-value | aOR (CI 95%) | p-value | |
| Age (ref: 18–20 years) | ||||
| 21–24 years | 0.85 (0.39–1.83) | 0.675 | 0.93 (0.39–2.23) | 0.876 |
| 25–35 years | 0.70 (0.30–1.63) | 0.412 | 0.95 (0.36–2.52) | 0.921 |
| Gender (ref: male) | ||||
| Female | 1.45 (0.74–2.84) | 0.280 | ||
| Education (ref: ≤ Primary school completed) | ||||
| Secondary school not completed | 0.74 (0.21–2.55) | 0.632 | ||
| ≥ Secondary school completed | 0.78 (0.21–2.88) | 0.712 | ||
| Age of first sexual intercourse (ref: < 15 years old) | ||||
| 15–18 years old | 2.27 (1.02–5.04) | 0.043 | 2.39 (1.01–5.66) | 0.046 |
| ≥ 18 years | 1.01 (0.35–2.95) | 0.988 | 0.87 (0.27–2.84) | 0.819 |
| Perceived Risk for HIV infection (ref: No risk) | ||||
| Some risk | 1.72 (0.49–6.01) | 0.395 | ||
| Previous to this study did you received information regarding HIV Vaccine research (ref: No) | ||||
| Yes | 0.86 (0.44–1.68) | 0.662 | ||
| Which of these sources have you received information about HIV vaccine research? (ref: None) | ||||
| Hospital/clinic/health worker | 0.66 (0.22–1.95) | 0.450 | ||
| Radio/Tv | 0.80 (0.39–1.66) | 0.548 | ||
| Friend/relative | 1.21 (0.42–3.52) | 0.724 | ||
| Research center | 0.42 (0.05–3.62) | 0.433 | ||
| Benefits of participating in Vaccine study (ref: No) | ||||
| Learn how to avoid risky behavior | 9.37 (4.42–19.89) | <0.001 | 4.28 (1.40–13.07) | 0.011 |
| Feel protected from HIV infection | 7.17 (3.31–15.51) | <0.001 | 3.41 (1.27–9.20) | 0.015 |
| Get free HIV counselling and testing | 2.81 (1.33–5.93) | 0.007 | 1.00 (0.35–2.89) | 1.00 |
| Receive updated information about HIV/AIDS | 1.69 (0.87–3.27) | 0.121 | ||
| Get small reimbursement | 1.43 (0.49–4.13) | 0.513 | ||
| Be tested for sexually transmitted infection | 5.26 (2.43–11.42) | <0.001 | 1.48 (0.47–4.70) | 0.503 |
| Receive regular health care related to research | 1.76 (0.91–3.41) | 0.094 | 1.29 (0.60–2.76) | 0.513 |
| How important are the following factors in making a decision about participating in a research study of an experimental vaccine? (ref: Not Important) | ||||
| Helping vaccine research | 0.82 (0.11–6.31) | 0.848 | ||
| Receiving support from family and friends | 1.17 (0.49–2.76) | 0.726 | ||
| Meet new people | 1.34 (0.54–3.36) | 0.530 | ||
| Helping the community | 1.00 (0.13–7.78) | 1.000 | ||
| Perceived as HIV positive | 0.94 (0.12–7.31) | 0.949 | ||
| Perceive as High-risk person for HIV infection | 0.43 (0.05–3.6) | 0.436 | ||
a) 10 participants who answered “Don’t know” were not included in analysis.
b) The multivariable analysis is a complete-case analysis, n = 534, and adjusted for all significant variables with p<0.05 and age as a controller.
OR Odds Ratio.
CI Confidence Interval.
aOR Adjusted Odds Ratio.